CompletedNot Applicable

Outpatient Left Laparoscopic Colectomy

France30 participantsStarted 2020-11-03

Plain-language summary

The success of the enhanced recovery program after surgery leads us to consider outpatient management of the colectomy. To this end, the investigators have designed an observational and prospective study of left laparoscopic colectomy on an outpatient basis. The objective is to assess the harmlessness of this management compared to standard management in the context of a public hospital.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * American Society of Anesthesiologists Classification (ASA) score I and II, * Patient with an indication for scheduled left colectomy due to neoplastic (stage 1) or diverticulitis, * Patient residing less than 30 minutes from La Rochelle hospital, * Presence of a companion from the anaesthesia consultation onwards, * Presence of an attendant at the patient's discharge, * Perfect understanding of outpatient care, pathology and surgical procedure of the patient and accompanying person, * Informed of the study. Exclusion Criteria: * ASA score 3 et 4, * Indication for a straight or transverse colectomy, * Neoplasia evolution \> stage 1, * Presence of anticoagulant treatment, * Intraoperative bleeding \> 500ml, * Conversion to laparotomy, * Severe anesthetic complication (Anaphylaxis, Difficult Intubation), * Persons deprived of their liberty by a judicial or administrative decision, * Persons of full age who are subject to a legal protection measure, * Persons unable to consent, * Persons who are not members of or beneficiaries of a social security scheme, * Patient's refusal to participate in the study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

30-day readmission rate

Timeframe: 30 days after surgery

Trial details

NCT IDNCT04310839

SponsorGroupe Hospitalier de la Rochelle Ré Aunis

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-11-02

View on ClinicalTrials.gov More Colonic Neoplasms trials